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ABSTRACT
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in a suitable phannaceutical carrier for administration to a
patient, are disclosed for treating or preveming gastric
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PHENYLBUTYL NITRONE COMPOSITIONS
AND METHODS FOR PREVENTION OF
GASTRIC ULCERATION

that it is su?iciently pronounced to overwhelm the antioxi
dative defense of the tissue, Curran, et al., Mol. Cell. Biol.
5, 167-172 (1985). In recent years, however, evidence has
been obtained that ischemia may cause conjugated dienes
and malondialdehyde to accumulate in the tissue. Even so,
it remains to be conclusively shown that free-radical damage
to unsaturated acyl chains in phospholipids, to protein, or to
nucleic acids constitutes an important role in the ischemic
necrosis. At present, the evidence is relatively strong for an
involvement of free-radical mechanisms in vascular injury,
and in damage a?ecting nerve and glial cells.
Although no drugs are currently approved for clinical use
in treating tissue damage due to ischemia, several com

Matter enclosed in heavy brackets [ ] appears in the
original patent but forms no part of this reissue speci?
cation; matter printed in italics indicates the additions
made by reissue.
The United States Government has certain rights in this
invention by virtue of grants from the National Institutes of
Health.

pounds have been proposed as potentially being effective.

BACKGROUND OF THE INVENTION

Mannitol, an oxygen scavenger, has been added to reperfu
sion media to limit damage to organs for transplantation.
Superoxide disrnutase (SOD) has been suggested as a means

This is a continuation-in-part of U.S. Ser. No. 07/422,651

entitled “Phenyl Butyl Nitrone Compositions for Treatment
of Oxidative Tissue Damage” ?led Oct. 17, 1989 by John M.
Carney and Robert A. Floyd, now U.S. Pat‘. No. 5,025,032.
This is generally in the area of compositions and methods

20

for use thereof for the treatment and prevention of gas
trointestinal ulceration resulting from the use of nonsteroidal
anti-in?ammatory compounds, wherein the active corn~

pounds are phenyl butylnitrone (PBN) or derivatives
thereof.
Gastric ulceration is among the most important of adverse

for limiting in vivo oxidative damage. The most promising
compounds that interfere with peroxidation generation are
the lazaroides. modi?ed prednisones, described by J. M.
McCall, Acta Anesthesia Belgica, First Antwerp int. Trauma
Symp., which have been reported to be e?icacious if given
during or after ischemia. White and Aust and co-workers,

25

Adv. Free Radical Biol. Med. l,l—l7 (1985), and Babbs,
Resuscitation l3, l65—l73 (1986), have demonstrated that
iron chelators protect animals from ischemia/reperfusion

reactions from aspirin and nonsteroidal anti-in?ammatory

injury.

drugs (NSAIDS). The currently accepted explanation for

It is therefore an object of the present invention to provide
composition and methods for use thereof which are useful in

NSAID-induced gastric ulceration is that NSAIDS inhibit

synthesis of cytoprotective prostaglandins, as reviewed by

preventing or treating gastric ulcers resulting from the use of

Whittle, B. R., and J. R. Vane. Arch. Toxicol. Suppl

non-steroidal anti-in?ammatory compounds.

7:315-322 (1984). This hypothesis is supported by the
demonstration that exogenous prostaglandins protect from
NSAID-related gastric ulcers by Graham, D. Y., et al. Lancet
2: 1277-1280 (1088), but challenged by recent studies show
ing that NSAIDS can inhibit gastric prostaglandin produc
tion without causing ulceration, as reported by Rainsford, K.
D., et al. Scand. J. Gastroenterol. 19 (Suppl 10l):35—68
(1984); Ligumsky, M., et a1. Gastroenterology 84:756-—76l

It is a further object of the present invention to provide
compositions and methods for use thereof which are useful
35

in preventing or treating pain and fever in vivo resulting
from infection and inflammation.

SUMMARY OF THE INVENTION

(1985); and Rainsford, K. D., “Relationship between drug
absorption, inhibition of cyclo-oxygenase and lipoxygenase
pathways and the development of gastric mucosal damage of

Compositions containing PBN, or active derivatives
thereof, in a suitable pharmaceutical carrier for administra

non-steroidal anti-in?ammatory drugs in rats and pigs". in
Advances in Prostaglandins, Leukotrienes and Lipoxins. M.
J. Bailey, editor. Plenum Press, New York, 639-653 (1985).
Thus, the cause of NSAlD-induced gastric ulceration
remains controversial, as reviewed by Rainsford, K. D.
Toxicologic Pathol. l6:251—259 (1988).

gastric ulceration caused by ingestion of non-steroidal anti
in?ammatories. The compositions have the following gen
eral formula:

Free radicals have been postulated to be mediators of

tion to a patient, are disclosed for treating or preventing
45

H

50

tissue injury including that brought on by ischernical reper
fusion damage. Important production sites of the oxygen

free radicals superoxide (02-) and hydroxyl (OH) radicals

wherein:
X is phenyl or

are the mitochondrial respiratory chain and the reaction

sequences catalyzed by cyclooxygenasc and lipoxygenase.

0*

\
/
C=N+
/
\Y
X

55

(0R)n

However, radicals are also formed during autoxidation of
many compounds (e.g., catecholamines). Ischemic events in
tissue causes a spurt of free-radical formation. This may be

due to oxidation of polyenoic free fatty acids, release and
reuptake of catecholamines, and oxidation of xanthine and
hypoxanthine by xanthine oxidase. Although all these events
occur during recirculation, when the O2 supply is restored

wherein R is H,
0

after ischemia, they represent metabolic cascades triggered
by agonistreceptor interactions, energy failure, and/or cal
cium in?ux during the insult. Although free radical forma
tion is a likely cause of ischemic damage, it has been di?icult
to directly demonstrate that such formation occurs and/or

ll
65

0
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phospbhocreatine (PC) in isolated perfused gastric mucosa.
Thus, aspirin and NSAIDS might be expected to produce

and n is a whole integer from 1 to 5; or
0

changes in the energy state of gastric mucosa similar to those

||

caused by ischemia, when ATP is depleted and then

NH——C—Z—;

degraded to hypoxanthine, as discussed by McCord, I . M. N.

Engl. J. Med. 312:158-163 (1985). Xanthine oxidase-me
diated ischemia-reperfusion injury of the stomach has

Y is a tert-butyl group that can be hydroxylated or

recently been reported as a cause of stress ulceration in

acetylated on one or more positions; phenyl; or

hemorrhagic shock, as reported by Itoh, M., and P. H. Guth.
Gastroenterology 88:1162-1167 (1985); Perry, M. A., et a1.
Gastroenterology 90:362—367 (1986); and Smith, S. M.,
Gastroenterology 92:950-956 (1987). If aspirin and
NSAIDS impair mitochondrial energy metabolism, the sub
sequent breakdown of high energy purines to xanthine might
also stimulate xanthine oxidase-mediated oxidant injury in
gastric mucosa, resulting in ulceration.

OW

wherein W is

It has now been discovered that, further to the methods

using PBN for the treatment and prevention of ischemic
20

damage, including by decreasing or preventing ATP deple
tion, described and claimed in U.S. Ser. N o. 07/422,651 ?led

Oct. 17, 1989, PBN, and derivatives thereof having spin
trapping activity, are useful in preventing or treating gastric
ulceration resulting from ingestion of non-steroidal anti

or Z; and

Z is a C1 to CS straight or branched alkyl group.
Based on animal studies, the dosage is in the range of 3
to 300 mg/kg and is administered prior to, simultaneously, or
shortly after ingestion of the NSAID compound(s). In the
preferred embodiment, the range is between 10 and 30

25

mg/kg, depending on the dosage unit required to protect the
mucosa. The preferred method of administration is orally,

formation, the free radical is no longer damaging to the cell.

alone or in combination with the non-steroidal anti-in?am
matory. It is believed that the PBN is also useful alone for

u-phenyl t-butyl nitrone (PBN), and derivatives thereof,
in a pharmaceutical vehicle suitable for administration to a

treatment or prevention of ulcers, aspects of diarrhea, gas

tritis, esophagitis, ileitis, and possibly pain and fever in a
manner analogous to analgesics such as aspirin and acetami

in?ammatories. As used herein, a free radical scavenger or
spin-trap reagent is a molecule that will form a stable
complex with a free radical. A free radical carbon trap is a
molecule in which the free radical is localized on a carbon
atom or a nitrogen atom. As a result of this chemical bond

35

patient, preferably by oral administration, are useful in
preventing or reversing gastric ulceration caused by the use
of non-steroidal anti-inflammatories (NSAID). PBN has a

nophen.

number of advantages in the treatment of gastric ulceration,
especially its complete lack of a measurable effect on normal
or uninjured cells. PBN is the preferred active compound at
this time, although a number of derivatives are also useful,

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is a comparison of the stomach from a piroxicam 40
treated rat (right) to the stomach from a vehicle control
including hydroxy derivatives, especially 2-, 3- or 4-hy

treated rat (left). Piroxicam at 23 mg/kg caused prominent

scavengers. The sul?iydryl scavenger dimethylthiourea

droxy PBN and mono-, di- and trihydroxy tert-butyl nitrone;
esters, especially esters which release 2-, 3, or 4-hydrox
yphenyl t-butyl nitrone such as the acetoxy derivative, 2-, 3-,
or 4-carboxyphenyl t-butyl nitrone, such as the ethyl deriva
tive, or phenyl hydroxybutyl nitrone, such as the acetoxy

(DMTU), 500 mg/kg i.p.) was given 24 hours and 1 hour

derivative; alkoxyl derivatives, especially lkoxyl derivatives

before piroxicam. The sulfhydryl scavenger N-acetylcys
teine (300 mg/kg), the hydroquinone acetaminophen (400
mg/kg) and the spin-trap phenylbutyl nitrone (PBN, 30
mg/kg) were given orally 1 hour before and along with
piroxicam. The antioxidant butylated hydroxytoluene (BHT,

which release 2-, or 4-hydroxyphenyl t-butyl nitrone, such
as the methyl derivative; and acetarnide derivatives, espe
cially acetarnide derivatives which release 2-, or 4 ami

ulceration along the ridges of gastric rugae.
FIG. 2 is a graph of % control ulceration from piroxicarn
versus the % ulceration in the presence of free radical

45

50

nophenyl t-butyl nitrone, such as the acetyl derivative;
diphenyl nitrone (PPN) and the analogous diphenyl nitrone

25 mg/kg/day i.p. in corn oil) was given for three days
before and again 1 hour before piroxicam. The % control
ulceration is determined by averaging the ratios of cm2
ulceration in control stomachs from rats given piroxicarn

derivatives. As used herein, “PBN” refers to both ot-phenyl

alone, and multiplyingxlOU. +P<0.0l compared to piroxi
cam alone.

DETAILED DESCRIPTION OF THE
INVENTION

Gastric parietal cells have abundant mitochondria to gen
erate the energy required for hydrogen ion secretion. Sali
cylate and NSAIDS have long been recognized as uncou

plers of mitochondrial oxidative phosphorylation, and
aspirin decreases mucosal adenosine triphosphate (ATP) and

60

t-butyl nitrone and derivatives thereof, unless otherwise
stated. The active agent in the compositions is N-tert-Butyl
(x-phenylnitrone (PBN) or derivatives thereof that are spin
trap reagents and in addition to chemical binding of free
radicals, may also act to prevent ATP depletion of cells.
The general formula for PBN and useful derivatives
thereof is:

65
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administered at varying intervals of time. Other methods of
administration can also be used, including subcutaneous,

wherein:
X is phenyl or

intravenous, and intraperitoneal administration. The pharv
maceutical compositions should provide a dosage of PBN

(OR)n

relative to the dosage of NSAID su?icient to protect the
mucosa from the e?ect of the NSAID. The concentration of

active compound in the drug composition will depend on
absorption, inactivation, and excretion rates of the drug as
well as other factors known to those skilled in the art. The
compositions are administered prior to, at the same time as,

wherein R is H,
0

0

or shortly after ingestion of the non-steroidal anti-in?am
matories. The e?ective dosage may also be determined

Y

position of the cells to damage resulting from depletion of
ATP (as demonstrated by in vivo NMR) and damage from

ll

based on that amount required to prevent or reverse predis

free radical generation. It is to be noted that dosage values
will also vary with the condition of the patient being treated.
It is to be further understood that for any particular subject,

and n is a whole integer from 1 to 5; or
0

ll

speci?c dosage regimens should be adjusted over time
according to the individual need and the professional judg

NH—C—Z—-,
20

ranges set forth herein are exemplary only and are not
intended to limit the scope or practice of the claimed

Y is tert-butyl group that can be hydroxylated or acety
lated on one or more positions; phenyl; or
OW

ment of the person administering or supervising the admin
istration of the compositions, and that the concentration

composition.
25

A preferred mode of administration of the active com

pound is in a form for oral delivery. Oral compositions will
generally include an inert diluent or an edible carrier.

Preferred pharmaceutical carriers for intravenous adminis—
tration are saline or phosphate buffered saline at physiologi

wherein W is

30

cal pH. Since PBN degrades at pH less than approximately
3 to 4, it is preferred to administer the PBN at a pH of 4 or
higher, or in combination with food or a bu?ering agent. For
oral delivery, the PBN may be enclosed in capsules, com‘

pressed into tablets, microencapsulated, entrapped in lipo
35

somes, in solution or suspension, alone or in combination
with a substrate immobilizing material such as starch or

poorly absorbable salts such as immodium. Pharmaceuti

cally compatible binding agents, and/or adjuvant materials
or Z; and

Z is a C1 to C5 straight or branched alkyl group.
The compositions can also contain other active agents,

can be included as part of the composition. The tablets or,

capsules may contain, for example, any of the following
40

such as lactose. Examples of commonly used NSAIDs

include aspirin, acetaminophen, ibuprofen, piroxicarn,
naphroxen, ?ufenamic and methanamic acid and related

nonsteroidal antiin?amrnatory compounds.

such as magnesium stearate or Sterotes; a glidant such as
45

Examples demonstrate the utility of the compositions in
preventing or treating ulceration resulting from ingestion of
NSAIDs. Exemplary dosages of PBN ranged from 3 to 300
mg/kg of body weight in animals. The effective range of

salicylate, or orange ?avoring. When the dosage unit form is

PBN in humans and other mammals is expected to be

the physical form of the dosage unit, for example, coatings
of sugar, shellac, or other enterie agents.
The present invention will be further understood with
55

administration for treatment or prevention and/or reversal of

EXAMPLE 1: COMPARISON OF
PIROXICAM-INDUCED ULCER WITH
CONTROL.

occur only in injured cells, and do not require the presence

of speci?c receptors, speci?c enzymes, and/or speci?c cell
types.
The PBN is preferably administered systemically, most
preferably orally, since this is the most rapid and e?icient
or may be divided into a number of smaller doses to be

reference to the following non-limiting examples demon—
strating methods for determining effectiveness of PBN
damage from NSAIDs.

little or no e?’ect on normal cells. The bene?cial effects

means for delivering the active compound to the site of free
radical generation. The PBN may be administered at once,

colloidal silicon dioxide; a sweetening agent such as sucrose
or saccharin; or a ?avoring agent such as peppermint, methyl

a capsule, it can contain, in addition to material of the above
type, a liquid carrier such as a fatty oil. In addition, dosage
unit forms can contain various other materials which modify

between approximately 10 and 300 mg/kg, preferably
between 10 and 30 mg/kg body weight. The compositions
can be effectively administered prior to, during or shortly
after ingestion of NSAIDs, and prevent or decrease the
extent of cellular damage.
Since the trapping of endogenous free radicals is speci?c
for only those cells that have been exposed to the conditions
that result in the production of free radicals, the traps have

ingredients, or compounds of a similar nature: a binder such

as microcrystalline cellulose, gum tragacanth or gelatin; an
excipient such as starch or lactose, a disintegrating agent
such as alginic acid, Primogel®, or corn starch; a lubricant

such as bu?‘ering agents such as antacids or inert carriers

The following materials and methods were used in

examples 1 and 2.
65

Animal Experiments.
Male Sprague-Dawley rats (Charles River, Wilmington,
Mass.) weighing 300-325 g were housed individually in

Re. 35,213
7

8

wire bottomed cages to prevent ingestion of hair and feces.
Animals were maintained without food for 48 hours and
without water for 24 hours prior to each experiment. Piroxi

or vehicle, stomachs are opened, washed with ice cold

saline, and spread along a flat surface with lumens exposed.
The gastric mucosa is then removed by scraping with a
surgical blade. The mucosa is homogenized on ice in 1 ml
of 1.15% KCl. Two aliquots of 250 p1 are snap frozen in
liquid nitrogen and stored at —70° C. for later determination
of total glutathione by the method of Anderson, M. E.

cam or aspirin and other NSAIDS were suspended in a

vehicle of l% carboxymethylcellulose, 0.1% Tween 80 and
0.15 M HCl, and administered in a volume of 1 ml on the

morning of study by oral gavage using an 18 gauge curved
blunt needle (Popper and Sons, New Hyde Park, N.Y.). One

Methods Enzymol 113:548-555 (1985) and protein by a
modi?cation of the Lowry method, described by Bennett, J.
P. Techniques Lipid Membrane Biochem. B408z1-22

ml of vehicle alone was administered for control experi
ments. HCl was added to the vehicle to insure an acid

environment in the stomach in all studies. Preliminary

(1982), using bovine serum albumin as a standard. Results
are expressed as nmole/mg protein. To measure oxidized

experiments showed that 23 mg/kg piroxicam consistently
produced ulceration, and this dose was used in all subse
quent studies. Four hours after the administration of NSAID
or vehicle, rats were euthanized with sodium pentobarbital
(100 mg/kg IP), and the surface area of ulceration per

glutathione (GSSG), the remaining 500 pl is mixed with an
equal volume of N-ethylmaleimide (NEM) in water (10 mM
?nal concentration of NEM), snap frozen and stored at -70°
C. After thawing for analysis, this mixture is passed over at

stomach was quantitated using morphometric techniques.
Stomachs were removed, the lumen was exposed by an

C-18 Sep-Pak column (Waters Associates, Milford, Mass.)

incision along the radius of greater curvature, and the
stomach was washed in phosphate buffered saline. The

and washed with 1 ml phosphate buffer (pH 7.5). This
technique for removing excess NEM has been previously

luminal surface was laid out on a ?at surface with gross folds 20 shown to result in >90% recovery of GSSG. GSSG is then

removed by gentle distension. The percentage of surface

assayed by the method used above to determine total glu

involved with submucosal hemorrhage was then determined

tathione.

by point counting, as described by Weibel, E. R. Stereologi
cal Methods: Practical Methods for Biological Morphom
etry. Academic Press, New York 1980. This was done by
tabulation of the percentage of points over ulcerations using
a point counting eyepiece graticle (16x16 points in a square
format). At the 22x magni?cation used on the Wild dissect

25

MEASUREMENT OF GASTRIC XANTHINE
OXIDASE ACTIVITY.

Xanthine dehydrogenase (XDH) and oxidase (X0) activi
ties are measured in whole stomach from piroxicam-treated

and vehicle-treated rats, using methods reported by Parks,

ing microscope (Wild-Heerbrugg, Basel, Switzerland), the

graticle covered a 1 cm2 area of the surface. Four to ?ve 30 et. al. Am. J. Pathol. 254 (Gastrointest Liver Physiol 17):
G768—G774 (1988). The artifactual conversion of XDH to
non-overlapping sampling sites were taken to fully cover the

X0 is minimized by quickly removing stomachs from rats
that were anesthetized with 50 mg/kg sodium pentobabital
and still breathing spontaneously. After gastrectomy, the rats

exposed surface. To determine the total luminal surface area,
the outline of the outer boundary of the stomach was traced
using a transparent acetate sheet, and the area was deter

mined from planimetry. The surface area of ulcerated 35 are euthanized by cutting the abdominal aorta. Stomachs are

regions per stomach was then determined by multiplying the
surface density of ulceration regions by the luminal surface

quickly rinsed in an ice cold homogenizing buffer consisting
of 50 mM potassium phosphate buifer, pH 7.0, containing 10

area of the stomach.

mM dithiothreitol (DTT), l mM phenylmethylsulfonyl ?uo
ride (PMSF) and 0.1 mM EDTA. The stomach is then
immediately immersed in liquid nitrogen and ground to a

MEASUREMENT OF LIPID PEROXIDATION IN
STOMACHS.

40

fine powder under liquid nitrogen using a mortar and pestle.

Lipid peroxidation is studied in piroxicam~and vehicle
treated rat stomachs by measuring thiobarbituric acid (TBA)

reactivity of gastric punch biopsies by the method of Buege
and Aust Buege, J. A., Aust, S. D. Methods Enzymol
5l:302—310 (1978). Four hours after piroxicam or vehicle,
stomachs are opened along the radius of greater curvature,
washed with ice cold normal saline, and spread along a ?at
surface with lumens exposed. Five punch biopsies from

45

About 0.5 g of frozen powder is added to 5 ml of homog
enizing buffer and centrifuged 40,000 g for 30 min. The
supernatant is decanted and rnicrofuged for an additional 10
min. Supernatants are not stored but assayed less than 2
hours after collection to prevent loss of activity.
The spectrophotometric assay used is based on production
of uric acid at 295 nm (lambda295=l.l z l04M_1cm_'). To

increase reaction rates activity was measured at 30 rather
mucosa] through serosal surfaces are taken from each stom 50 than 25° C. One ml reaction mixtures contained 500 pl
ach using a 3 mm diameter skin biopsy punch. Biopsies are
sample, 50 M xanthine and 100 M EDTA in 50 mM
taken over ulcers in piroxicam treated stomachs and ran
potassium phosphate buffer, pH 7.8 X0 is assayed in the
domly over gastric rugae (where ulcers occur) in vehicle
absence in NAD+, while XDH +X0 activity is measured in
control stomachs. Biopsies from each stomach are com
the presence of 500 M NAD+. Enzyme activities are
bined, homogenized on ice in 1 ml of cold 1.15% KCl, and 55 reported as international units (1 pmol of urate formed per
mixed with 2 ml of TBA reagent (0.375% thiobarbituric acid
min.). The extent of XDH conversion (% X0) is calculated
and 15% trichloroacetic acid in 0.25 HCl, to which 0.01%
from X0 activity divided by XDH+X0 activity.

butylated hydroxytoluene is added just prior to use). After
incubation at 100° C. for 15 minutes, the mixture is cooled
and centrifuged at 1,500 g for 10 min. The absorbance of the 60
supernatant is measured at 532 nm, and results expressed as

A532 per stomach.
MEASUREMENT OF GLUTATl-IIONE IN
GASTRIC MUCOSA.

Gastric mucosa] glutathione is measured in piroxicam
and vehicle-treated rat stomachs. Four hours after piroxicam

65

Studies of Mitochondrial Respiration.
Rat liver mitochondria are prepared using the method of

Lai and Clark Methods Enzymol 55:5l—60 (1979). The
livers are excised rapidly into ice cold isolation medium
containing 0.25M sucrose, 10 mM tn's(hydroxymethyl)ami
nomethane (Tris), 0.25% bovine serum albumin (fatty acid
free), and 0.5 mM potassium EDTA, pH 7.4. The tissue is
minced and rinsed three times in cold isolation medium. The
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cold isolation medium, gently homogenized, and diluted

Introduction to statistical methods, 4th edition. (New York:
McGraw Hill, 1983). The effect of treatment interventions

with an additional 10 ml of isolation medium. The homo

on NSAID-induced ulceration are displayed graphically as

minced tissue is placed in a Dounce homogenizer with 20 ml

% of control ulceration, determined by summing the ratios

genate is centrifuged at 2,000 g for 3 min., and the resulting
supernatant recentrifuged at 12,500 g for 8 min. The crude
mitochondrial pellet is suspended in 0.12M mannitol-0.03M
sucrose medium containing 3% Ficoll, gently layered onto
20 ml of 6% Ficoll (0.25M mannitol-0.06M sucrose), and
centrifuged at 11,500 g for 30 min. The resulting mitochon
drial pellet is resuspended in the isolation medium and
recentrifuged for 10 min. at 12,000 g. The ?nal pellet is

of cm2 ulceration in each treatment stomach to the mean cm2

ulceration of respective untreated N SAID control stomachs,
and multiplying +100. In vitro studies are compared using
the Student’s unpaired T-test, Dixon, W. J., Massey, F. J ., Jr.
Introduction to statistical methods, 4th edition. (New York:
McGraw Hill, 1983). Values are expressed as meaniSEM.
Signi?cance is assumed when P<0.05.

brought to a concentration of 10 to 15 mg of mitochondrial

protein per ml with isolation medium. Mitochondrial protein
is determined by the Biuret reaction described by Gornall, A.
G., et al. Biol Chem 1771751-766 (1949), using bovine

Reagents and Pharmaceuticals
15

serum albumin as a standard. Mitochondrial respiration is

maceuticals are from Sigma Chemical. Piroxicam caused

measured polarographically in a magnetically stirred cham
ber at 25° C., using a Clark rnicroelectrode (Diamond
Electro-tech, Ann Arbor, Mich). The incubation medium

contains the following (in mM): 5K+, 226 mannitol, 75

20

profound gastric ulceration. FIG. 1 shows that piroxicam
induced ulcers usually occurred only on the ridges of gastric
rugae and spread linearly along these ridges, without
involvement of the remaining gastric surface area. In the

sucrose, 5 Tris~phosphate, l0 Tris-Cl, and 0.05 EDTA at pH
7.4. State 4 respiratory rates are determined using both
NADH-linked (2.5 mM malate+2 rnM glutamate) and
FADl-lz-lined (10 mM succinate) substrates, with 5 mM KCl
at pH 7.0. State 3 respiration rates are measured after
stimulation with 1.5 mM ADP. Respiratory control ratios are
determined as the ratio of State 3 to State 4 respiration after

Phenyl N-tert-butyl nitrone is obtained from Aldrich
Chemicals, Milwaukee, Wis. All other chemicals and phar

absence of an intervention, a mean of 0.215 cm2 ulceration

25

was present in piroxicam-treated control stomachs. How
ever, the degree of ulceration in this highly stress-dependent
model was variable, ranging among experiments from
0.0310009 to 070610.104 cmz. For this reason, each treat
ment intervention was compared to its own group of control

rats that were fasted simultaneously and treated with piroxi

incubation with 0, 50, 100 and 200 11M piroxicam.

cam at the same time.

Studies of Microsomal Lipid Peroxidation.

30

EXAMPLE 2: SUPPRESSION OF
PIROXICAM-INDUCED ULCERS BY FREE
RADICAL SCAVENGERS.

Microsomes are isolated from rat livers by modi?cation of

the method of Fleisher and Kervina, Methods Enzymol
3117-41 (1974). Rats are euthanized by C02 narcosis. The
livers are excised rapidly into cold isolation medium con

taining 0.1M sodium phosphate and 2 mM EDTA, pH 7.4.
The tissue is minced and homogenized in 3 ml isolation
medium per gram of tissue using a Potter-Elvehjarn homog
enizer. The homogenate is centrifuged at 17,800 g for 20
min., and the pellet discarded. The supernatant is recentri
fuged at 100,000 g for 60 min. The resulting pellet is
resuspended in isolation buifer and recentriguged at 100,000
g for 40 min. The ?nal pellet is resuspended in storage buffer
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Piroxicam was selected as a model NSAID because it is

highly ulcerogenic in rats and mice, yet is a relative weak

reversible inhibitor of prostaglandin synthesis. The spin trap
phenylbutyl nitrone (PBN) was used to explore the role of
free radicals and oxidative events mediated by xanthine
40

oxidase- and iron-mediated oxidant injury in the pathogen
esis of piroxicam-induced gastric ulcers. In each experiment,
the surface area of gastric ulceration produced by piroxicam
in 15 treated rats was compared to that in 15 rats of the same

containing 100 mM potassium phosphate, 20% glycerol, 1

age and size that were fasted simultaneously but which

mM EDTA, 1 mM DTT and 20 M butylated hydroxytolu
ene, pH 7.25. This suspension is frozen under liquid nitrogen

received no intervention. Phenylbutyl nitrone (30 mg/kg)
was given orally in water 1 hour before piroxicam and also

and stored at —70° CL until use. Microsomal protein is

added to vehicle when piroxicam was administered. When

determined by a modi?cation of the Lowry method of

intervention were given with piroxicam, the pH of the ?nal
mixture was adjusted if necessary to equal that of piroxieam
and vehicle alone.
To generalize the ?ndings relative to piroxicam to other

Anderson, M. E. Methods Enzymol ll3:548—555 (1985).
The effect of 200 M piroxicam on microsornal lipid per
oxidation is studied by incubating l mg microsomal protein
in 100 mM potassium phosphate, pH 7.25, on a shaking

50

NSAIDS, the elfect of PBN, administered as above, can be

water bath at 37° CL for 90 min., with and without the
addition of 2 mM NADPH or 1 rnM EDTA. Lipid peroxi

dation in the 1 ml reaction mixture is measured by mixing
with 2 ml TBA reagent and assaying for thiobarbituric acid
reactivity by the method of Buege and Aust. Values are
expressed as the increase in absorbance at 532 nm (A532) per
mg microsornal protein and represent the mean of three

compared with the e?’ect on gastric ulceration from aspirin
55

(200 mg/kg), di?unisal (125 mglkg), naproxen (150 mg/kg)
and ibuprofen (230 mg/kg).
Piroxicarn-induced ulcers were markedly reduced in rats
treated with free radical scavengers, as shown in FIG. 2,

suggesting that generation of reactive oxygen species is an

Statistical Analysis.

important mechanism in the pathogensis of piroxicarn-in
duced ulcers. In ulcerations/unit area, piroxicam only pro
duced 0229:0145 ulcerations/unit area, and piroxicam plus

Mann-Whitney U Test, Dixon, W. 1., Massey, F. J., Jr.

treated with piroxicarn alone (019410.039 cm2 ulceration in

replicates.

PBN produced 0.077i0.l04 ulcerations/unit area, statisti
cally signi?cant at p<0.0052. In contrast, ascorbate, a reduc
Di?'erences in total luminal surface area in cmz, surface
ing substance that is well-recognized to facilitate iron
area of ulcerated regions per stomach and bio-chemical
analyses between each treatment intervention and its corre 65 dependent generation of reactive oxygen species, increased
ulceration by over 600% compared to control stomachs
sponding untreated control group are compared using the
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ascorbate-treated stomachs vs 0.031i0.009 cm2 in stomachs

administering to a patient in need of such treatment

receiving piroxicam alone, P<0.00l. In support of an oxidant
mechanism as the pathogenesis of ulcers from piroxicam,
thiobarbituric acid reactivity was signi?cantly increased in
gastric biopsies from piroxicam treated rats compared to rats
treated with vehicle alone (A532=0.l04iO.0l0 for piroxicam

ot-phenyl t-butyl nitrone [and derivatives] or a deriva
tive thereof [having spin-trapping activity and prevent
ing ATP depletion in vivo in tissue] having the formula:

vs 0.075i0.004 for vehicle treated stomachs, P<0.05).
Piroxicam also decreased total glutathione in gastric mucosa

(03310.03 nmoles/mg protein) compared to vehicle alone
(0.042i0.07 nmoles/mg protein) and increased the fraction

Y

Y

O

wherein:
X is phenyl or

of GSSG (8.9i0.9 for piroxicam vs 6.4 0.7% for vehicle),
although these differences failed to achieve statistical sig
ni?cance.

Xanthine oxidase activity was readily identi?ed in whole
stomach. Piroxicam treated stomachs had 30.5il.6 mU/g of
total XHD+XO activity, of which 455% was X0. Vehicle
treated control stomachs had 3l.6i2.45 mU/g X. Piroxicam
increases the rate of mitochondrial oxygen uptake in the
absence of ADP (State 4) and that normal stimulation of
respiration by ADP (State 3) is lost in the presence of

(OR)n
t. . 5

wherein R is H,

piroxicam. This inhibition of respiratory control by piroxi
cam was demonstrated for both FADHZ-linked and NADH
linked substrates. However, piroxicam did not increase

Y

generation of OZ-by mitochondrial respiration. Piroxicam
had no effect on NADPH-dependent microsomal lipid per 25
oxidation.

and n is a whole integer from 1 to 5; or

Aspirin (0.972i-0.3l8 cmz), di?unisal (0597:0103 cmz),
naproxen (0370:0056 cm2) and ibuprofen (0644:0110
cmz) also caused severe gastric ulceration. In summary,
ulceration from piroxicam was markedly inhibited by the

spin-trap PBN.
Y is a tert-butyl group that can be hydroxylated or
EXAMPLE 3: NON-TOXICITY OF PBN AND
BIOAVAILABILITY.

acetylated on one or more positions; phenyl; or
35
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Previous studies on mutagenicity using standard tech
niques have demonstrated that PBN and analogs thereof are
not mutagenic. In addition, in vitro cytotoxicity tests using
human lymphocytes have indicated that PBN in concentra

tions of up to at least 100 prnolar have no cytotoxic elfect. 40
In vivo toxicity tests have indicated the following. Acute
doses PBN in doses up to 3 g/kg in rodents have no adverse
e?ects. An LD50 has yet to be determined because of the lack
of toxicity. Acute i.v. doses of PBN ranging from 10 to 300 45

mg/kg body weight (injected within 60 seconds) have no

acute toxic etfects in gerbils. Continuous i.v. administration
of PBN at a dose of 50 mg/kg/hr for a total of 48 hr has no

adverse effect on gerbils.
An estimate of the bioavailability of PBN demonstrates
that it is widely available throughout the body and is able to
cross all of the barriers to distribution, including the blood
brain barrier (the brain shows 80% of the plasma concen

SO

or Z; and

Z is a C1 to C5 straight or branched alkyl group; and
a pharmaceutically acceptable carrier for oral administra
tion to a patient, in a dosage effective to treat or prevent

tration). Limited pharmokinetic studies indicate that the

gastric ulceration from ingestion of nonsteroidal anti

inflammatory compounds.

plasma half-life in the rat is three to four hours.
Modi?cations and variations of the present invention,

compositions containing PBN and derivatives thereof, and

2. The method of claim 1 wherein the phenyl butyl nitrone
derivatives are selected from the group consisting of

methods using the compositions for the treatment or pre

hydroxy PBNs, PBN esters, acetoxy PBNs, alkyl PBNs,

alkoxyl PBNs, phenyl PBNs.

vention of gastric ulceration resulting from ingestion of
non-steroidal anti-in?ammatories, will be obvious to those
skilled in the art from the foregoing detailed description.

60

the group consisting of 2-, 3-, and 4-hydroxyphenyl t-butyl
nitrone; 2-, 3-, and 4-hydroxyphenyl t-butyl nitrone; 2-, 3-,
4-carboxyphenyl t-butyl nitrone; and 2-, 3-, and 4-ami

Such modi?cations and variations are intended to come

within the scope of the following claims.
We claim:
1. A method for in vivo treatment or prevention of gastric
ulceration from ingestion of non-steroidal antiinllammato

ries comprising:

3. The method of claim 1 wherein the PBN derivative is
functionalized to release in vivo a compound selected from

65

nophenyl t-butyl nitrone.
4. The method of claim 1 comprising as the active

ingrdient ot-phenyl t-butyl nitrone.
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5, The method of claim 1 wherein the PBN [and deriva

and n is a whole integer from 1 to 5; or

tives] or a derivative thereof is in a pharmaceutical carrier
delivering an effective dosage to a patient to treat or prevent

gastric ulceration from simultaneous ingestion of nonsteroi

dal antiin?ammatory compounds.
6. The method of claim 1 wherein the PBN [and deriva
tives] or a derivative thereof is in a pharmaceutical carrier
delivering an effective dosage to a patient to treat or prevent

Y is a tert-butyl group that can be hydroxylated or
acetylated on one or more positions; phenyl; or

gastric ulceration from subsequent ingestion of non-steroi
dal anti-inllammatoriy compounds.

OW

7. The method of claim 6 wherein the non-steroidal

anti-in?ammatory is selected from the group consisting of

aspirin, acetaminophen, ibuprofen, piroxicam, naproxen,
?ufenamic and methanamic acid and related nonsteroidal 15

antiin?ammatory compounds.
8. The method of claim 1 wherein the PBN [and deriva
tives] or a derivative thereof is provided in a dosage of

between 3 and 300 mg PEN/kg body weight.
9. The method of claim 8 wherein the PBN[and

20

derivaties] or a derivative thereof is provided in a dosage of

between 10 and 30 mg/kg body weight.
10. The method of claim 1 wherein the PBN [and deriva
tives] or a derivative thereof is provided in combination
with a pharmaceutical carrier selected from the group con

or Z; and

Z is a C1 to CS straight or branched alkyl group; and
a pharmaceutically acceptable carrier for oral administra
tion to a patient, wherein the a-phenyl t-butyl nitrone
[and derivatives] or a derivative thereof is in a dosage
elfective to prevent or treat gastric ulceration by non

sisting of microcapsules, liposomes, immobilizing sub
strates, salts that are poorly absorbed through the gas

trointestinal lining, oils, and buffering agents.
11. A composition for in vivo treatment or prevention of
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gastric ulceration comprising:
Ot-phenyl t-butyl nitrone [and derivatives] or a derivative

said agents being present in effective amounts.
12. The composition of claim 11 wherein the phenyl butyl

thereof [having spintrapping activity and preventing
ATP depletion in vivo in tissue] having the formula:
H

5 nitrone derivatives are selected from the group consisting of

hydroxy PBNs, PBN esters, acetoxy PBNs, alkyl PBNs,

O

alkoxyl PBNs, phenyl PBNs.

\ GIN»/
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steroidal antiin?amrnatory compounds wherein the
PBN [and derivatives] or a derivative thereof is in
combination with a non-steroidal anti-in?ammatory,

13. The composition of claim 11 wherein the PBN deriva
tive is functionalized to release in vivo a compound selected

Y

40

wherein:
X is phenyl or

from the group consisting of 2-, 3-, and 4-hydroxyphenyl

t-butyl nitrone; 2-, 3-, and 4-hydroxyphenyl t-butyl nitrone;
2-, 3-, and 4-carboxyphenyl t-butyl nitrone; and 2-, 3-, and
4-aminophenyl t-butyl nitrone.
14. The composition of claim 11 comprising as the active

ingredient ot-phenyi t-butyl nitrone.

(0R)n
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15. The composition of claim 11 wherein the PBN [and
derivatives] or a derivative thereof is in a pharmaceutical

carrier delivering an effective dosage to a patient to prevent
injury from simultaneous ingestion of a non-steroidal anti

in?ammatory compound.

wherein R is H,
o

ll

50
0

16. The composition of claim 11 wherein the non-steroi
dal anti-in?ammatory is selected from the group consisting

of aspirin, acetaminophen, ibuprofen, piroxicam, naproxen,
?ufenamic and methanamic acid and related nonsteroidal

antiin?ammatory compounds.
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